๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
ICON Public Limited Company (ICLR)
NASDAQ: ICLR ยท Real-Time Price ยท USD
186.71
-3.65 (-1.92%)
Nov 20, 2026, 4:00 PM EST - Market closed
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Demand has strengthened for five straight quarters, with direct-fee book-to-bill at 1.3x and expanded biotech reach. Technology-led execution, outcome-based contracting and selective investment support growth and a multi-year margin recovery.

Dave Windley
Healthcare Equity Research, Jefferies

Okay. All right. Hi, good afternoon, everybody. I'm Dave Windley with Jefferies Healthcare Equity Research in the States. I cover the CRO space. Pleased to have the ICON management team here with us. Pleased to have all of you in the audience and anybody listening in on the webcast as well. Thank you for your interest in Jefferies Healthcare Conference. We are proud of the growth that we have seen in the conference. Thank you to the ICON management team for joining us. Barry Balfe, the company's CEO, been in that seat for a little over a year, approaching a year?

Barry Balfe
CEO, ICON Public Company

Just over.

Dave Windley
Healthcare Equity Research, Jefferies

Just over. Right 3Q of last year. But 20 years with the company, plus. And Nigel Clerkin, the company's CFO, who joined in 2024. Appreciate both of you being here. I think, Barry, you wanted to start off with a couple of comments, and then I've got some easy questions for you.

Barry Balfe
CEO, ICON Public Company

It wouldn't be like you if you did, Dave. Look, I'll be very brief, looking forward to the Q&A. I think we meet at an interesting time. There has been much commentary on the demand environment for drug development services in recent times, CRO services in particular. We're probably now in the fifth straight quarter of demonstrably improved demand environment, and thankfully, probably in the fourth or fifth straight quarter where I think ICON is outcompeting a peer set in terms of converting on that demand environment. We feel good about both of those dynamics. But it's also an interesting time as we continue to navigate the confluence of twin revolutions in technology and in biomedical science. It is not an exaggeration to say that we can literally sequence millions of times more molecules than was the case a generation ago.

The question is, how can companies like ourselves help pharma and biotech sponsors to make better bets and convert them to market or failure faster, more cost-effectively, and more predictably? A lot of what we have been talking about with our customers in the last year or so really talks about where ICON needs to sharpen its commercial focus to do just that and sharpen our strategic focus to do just that. It is often said that the CRO industry is poorly differentiated. While I agree that is largely true, it is also true that this is a company that seeks to differentiate in how we partner every bit as much as the capabilities that form the basis of those partnerships. We talk a lot with our customers about co-investment. We talk a lot with our customers about transformation.

We talk a lot with our customers about the need to put these emergent technologies in the hands of subject matter experts who know how to convert them into capability, into time, and into data insights rather than just data. I imagine, Dave, that is a lot of what we will be talking about here today. So I will pull up there, thank everybody for their attention, and submit myself to the inquisition.

Dave Windley
Healthcare Equity Research, Jefferies

All right. That is a good tee-up. So I do want to start with where you started on the demand environment and your outcompeting peers. So ICON's bookings have not just outpaced but well-outpaced peers for now four quarters, so much so that the market, I think, has questions about where is all that business coming from. So I would be very pleased for you to describe the factors that are helping to lift your book-to-bill from, as you have described, what was about a 1.0 in the two years ago period to what is now a 1.3 on a service fee basis in the trailing one-year period.

Barry Balfe
CEO, ICON Public Company

Yeah. I think the first thing to say is that the preceding period of a year or maybe even two years was the abnormality. Right now is better than a historical average, but that was much, much worse than a historical average. It is probably no secret to our attendees and listeners today that pharma went through a period of some hesitancy. We had biotech funding challenges, not just in raising capital but deploying them. We had large pharma deprioritizing out of certain areas with something of a lag before they reprioritized back into others. This was all set against the backdrop of IRA, MFN, and loss of exclusivity in relatively swift succession. It is fair to say that healthcare was too much on the front pages and not enough on the business pages and the healthcare pages of our newspapers. So I think some of this is right-sizing.

But it is also true that we came out in the first quarter of 2025, and we talked about certain areas where we were going to sharpen our focus. We are already alliance partners of 18 of the top 20 pharma companies, but I was pretty clear in February of 2025 that I did not think we were diversified enough within those accounts. There was an opportunity for us to partner in FSO and FSP and Labs and kitting and early phase and evidence generation and technology services and site networks rather than one or two of those services. And I am pleased to say we have seen good conversion on that. So alongside sustained, robust growth in our FSP business, I think the robustness of the large pharma full outsourcing trends in the last 18 months have perhaps been ahead of other people's expectations.

And unsurprisingly, given that ICON wins about two-thirds of what we touch in that space, that is an area where we have profited disproportionately. In the midsize segment, I think I am on record multiple times as having said I thought we were too transactional in our approach. We were working with these companies rather than partnering with them sufficiently strategically on a preferred partnership or alliance basis. And I do not think there has been a quarter since, correct me if I am wrong on this. I do not think there has been a quarter since in which we have not rolled up some of those transactional relationships into formalized alliance partnerships. That has certainly been a tailwind to the commercial performance. And in biotech, Dave, you and I have spoken many times. I did not feel that this company was seeing enough of that biotech market.

We are now engaged with 30% more biotech companies than we were just one year ago, and we saw a significant uptick in RFP flow. If RFP flow was up 7%-ish, high single digits across the business in the last 12 months, over the last 24 months, it is up substantially in biotech specifically. Still a bit to do on win rates in that space. You know, we win roughly consistently about one in four of the dollars we bid on rather than the one in three I think we should be winning or perhaps better. So there is more to do there. But I think you are really seeing the product of more benign environment, and superior execution, which to a significant degree is underpinned by some of the technology bets we have made.

And maybe I will just finish by saying it is okay, in fact, necessary to align ourselves with the large-scale transformational agenda that AI represents, but that is just a ticket to entry. In order to win, and especially to win disproportionately, we have to be able to produce innovation that creates value now.

And we gave some examples of why we think that is resonating with customers in our most recent earnings call. To take 27%, 28% of the cycle times out of simple things like SDTM and programming cycle times is value today. To take 10% and then 20% and then 30% out of site contracting cycle times is value today. To be able to roll out monitoring agents and other agentic capabilities, put them in the hands of our teams to generate better data insights, make better decisions, and return better intelligence to our customers is generating value today.

And I think increasingly, we're seeing win rates being driven by not just alignment with longer-term transformation, but the ability of SMEs to turn commercially available tools into bespoke capability.

Dave Windley
Healthcare Equity Research, Jefferies

I want to drill in on a couple of these things. When you talk about conversations with these clients around co-investment and co-transformation, when you say co-investment, can you describe what you mean by that?

Barry Balfe
CEO, ICON Public Company

Well, a lot of the time, capital's finite everywhere, right? So we were very serious about saying that a lot of where we make our investments will be driven by where our customers have or would like to make theirs. So you go to a customer that's thinking about experimenting with a monitoring agent like Meridian that I just talked about, and you say, "Well, why don't you fund your next favorite bet, and we'll give you access to this, and that's capital that you can free up." In other cases, it's about saying, "Well, you could only fund your five favorite ideas. What was your sixth? Because maybe it aligns with our roadmap." So a lot of these large-scale partnerships will include a commitment to shared innovation, shared innovation dollars very often.

And there's very often a significant synergy between where we were going to sell dollars anyway, and with a slight tweak, it now overlaps with a very significant business interest of our customers. That's always been true of large pharma. I think the more recent trend is midsize companies starting to buy in a more strategic fashion that's more akin to large pharma and even biotech companies. I mean, in the last quarter, we said we'd converted three transactional relationships into enterprise preferred partnership relationships. I think biotechs of scale, certainly not the earlier phase emerging biotechs, are seeking to have partnerships that will be around for the longer term and better informed by their needs. So they're the kind of things we're talking about.

Dave Windley
Healthcare Equity Research, Jefferies

Got it. In that next point, you had quantified RFP flow. I think you said 7% increase overall. Your point was to emphasize that biotech is up much, much more than that. The point you just made about rolling a transactional relationship into more of an alliance enterprise-type partnership, how could you quantify the difference that that makes in what you will see or what you think your win rate will change in terms of, you know, transactional to alliance?

Barry Balfe
CEO, ICON Public Company

You get some people who go all in with one provider for a sole asset or multiple assets. You will get others that say, "We are only going to talk to two people because we are getting insufficient ROI from putting bids out to tender with, you know, half a dozen companies. It is just time, cost, and maybe not a whole lot of value." The three that we talked about last quarter, I think one of them was a sole providership, and the other two were not, but they were a very significant consolidation of the partner base for those companies. It allows us to resource with a little more clarity.

It allows them to be assured that that resourcing will be done in advance on a prospective basis, that we are not running around looking to free up experts at the last minute because we converted an opportunity we had less clarity on. One of the things we talk about a lot at ICON is meeting customers where they are. And I say very often, "I am happy to take risk. I am happy to resource on a maybe." That is one of the reasons to have a CRO partner.

If you are 60% likely to need an expert resource, we are happy to go procure one or ring-fence one for you on the basis that if you do not ultimately need it is much easier for me to defer that exposure onto other customers than it is for a biotech customer either to do it themselves or to wait till the last minute to ask for one and potentially have to wait in line. I think it is a smaller-scale model of the partnering capabilities that have served us so well in large and midsize pharma.

Dave Windley
Healthcare Equity Research, Jefferies

Okay. Another question, a little more tactical, but you answered in an earlier conversation. I want to put it on the mic is, around the lift in your booking strength, how much of that relates to backlog that you removed prior in your, you know, your backlog clean-out and your cancellation definition change, any of that that has come back into the bookings since then?

Barry Balfe
CEO, ICON Public Company

One small study. I have heard some speculation to the contrary. I am happy to put it to sleep. Pressure makes people say funny things. One small study. People might be aware that Nigel and I took the decision that the company's backlog management policy was not optimal in one specific respect, in that it required a written cancellation from a customer in order for something to come out of backlog. I felt that was not the right thing to do. If a study is on indefinite hold, if it no longer meets the very strict criteria that were required for it to go into backlog in the first place, I think it should come out. That means sometimes if a customer is held up in a manufacturing issue or a regulatory issue, we will elect to take something out of backlog to be more conservative in that respect.

If that study comes back to life in a future period, we will be happy to clarify it, and we will be happy to include it. But I do not see value in things that aren't burning, hanging out in backlog. It makes modeling more difficult for the market. It makes, frankly, resourcing projections more difficult for me, and we took the opportunity to clear that up.

Dave Windley
Healthcare Equity Research, Jefferies

Yep. I believe you said that dollar value is in the neighborhood of $30 million-$40 million?

Barry Balfe
CEO, ICON Public Company

I think approximately $30 million.

Dave Windley
Healthcare Equity Research, Jefferies

Yeah, yeah.

Barry Balfe
CEO, ICON Public Company

Very small is the answer.

Dave Windley
Healthcare Equity Research, Jefferies

Yep. While we are on this subject, the other thing that is different to my ear in your messaging since you took over is this willingness to meet the client where he or she is, bend your capabilities to what they need, and in some cases, kind of put your money where your put your performance where your mouth is around, committing savings to clients. Maybe talk about those structures and then how prevalent they are or are not.

Barry Balfe
CEO, ICON Public Company

I'm not sure it's new. I'm perhaps just in a position to amplify that thinking a little more from this seat. I mean, in essence, I don't know an established company that doesn't execute its business to a certain degree in-house with in-house resources, in-house with our resources, or in our house with our resources, right? So in-house, insourced, outsourced. That's generally the triumvirate. And it's incumbent upon any CRO that wants to lead in this sector to meet those customers where they are. We sit on a wealth of expertise, a wealth of human capital, and a wealth of data, right? Plus or minus the technology, that's pretty much what we have. The trick in our business is to be able to configure those things such that the user experience is value-add, is simple, and is cost-effective. We're very keen to do those things.

Frankly, the migration away from effort-based contracts to outcomes or milestones-based contracts works in everybody's favor. Your customers don't want to incentivize you to sell them more people, and I don't want to be locked in an ever-decreasing circle of race to the bottom on headcount rates. If I go to a head of R&D tomorrow and say, "I can knock 10% off the price of a study or 10% off the entire cycle time of running drug development programs in your company, 10% off the price of an entire function," it will be the latter two categories that appeal disproportionately for obvious reasons. It's not just cost, which is a ticket of entry, right? That's table stakes here. What we also need to be able to do is to influence enterprise strategy and enterprise rates of conversion within our customers.

For us to be able to go in and say, "We think you're 20% too slow or too expensive in a function. Let us do it our way, and we'll underwrite the first 10%, but we want to gain share in the remainder or the upside," is good business for everybody. I think these things are increasingly appealing. In the FSO business, Dave, I said before, in the space of about two years, we went from 60% unit-based contracts to 40%, outcomes or milestone-based contracts to 40/60 in the space of about 18- 24 months. So it was relatively rapid. It's relatively prevalent. The exception is in FSP, where I'm still confounded by just a very large proportion of these deals that are headcount-based.

I think we will see increasingly an emphasis on outcomes-based functional outsourcing in the true sense of the word rather than just capacity management models where we're giving customers human capital that may not be deployed as effective.

Dave Windley
Healthcare Equity Research, Jefferies

Okay. I'm inclined to dig in on the milestone-based, which so I want to clarify because I hear this terminology that, you know, milestone can apply to more of a cash flow billing achievement within a contract like you achieve first patient in, and so you can release, you know, the next 10% or 20% or whatever percent of the contract value versus milestone as defining the revenue, you know, the revenue earned. My understanding is that milestone still really more applies to the cash flow drivers, but I want to give you the opportunity to set me straight.

Barry Balfe
CEO, ICON Public Company

Well, I think it's both, right? Because if you get to the 100% milestone, that's 100% of the contract realized. If you do that more efficiently, your customer wins because they get their deliverable early, and you've done it faster and presumably with fewer resources consumed, and therefore, there's a margin opportunity. On a unit-based contract or an effort-based contract, when we come in earlier, the customer has 100% of the value and sometimes doesn't feel like the CRO partner is incentivized to find it. Now, we tend to take a longer-term view. I think anybody who aligns themself with inefficiency or the status quo is likely not to be a factor in this sector for terribly long. But the underlying commitment, not just to payment schedules, but to contract values on that basis, I think is a rising tide that really does raise all boats.

Dave Windley
Healthcare Equity Research, Jefferies

Okay. I want to move still within kind of a bookings demand, question series, but on pass-throughs, which is a nice boring topic and one that I'm sure you'd love to talk about. But the pass-through intensity seems to me to be a structural secular factor. It may wax and wane, but the technology intensity of trials, both medical technology and information technology, site inflation costs, things like that are driving pass-throughs. How much of that do you see? Maybe as we talked about after the third quarter, the intensity of pass-throughs in the bookings that you've seen recently are in part, you know, the composition of what you've won, but also in part the fact that you don't include FSP fully in those bookings. So, you know, kind of level set on how pass-through intensity is changing.

Barry Balfe
CEO, ICON Public Company

Well, I'll give you an opening comment, and then I'll ask Nigel to expand on the implications for the model. The first thing to say is pass-throughs are zero calorie. We make no margin on them. So if the pass-through carry on a study, a program, or a business unit doubles or halves, I don't particularly care. What is important to note, though, is the relative impact of healthcare inflation. It is probably a surprise to nobody that the inflation and the cost of doing things in a healthcare setting in the United States in particular is multiples of the inflation of running clinical trials, more generically, on the CRO side, for example. So the price of monitoring a site, we're getting increasingly more efficient.

The price of buying FibroScans, biopsies, MRIs, whatever else we might ask physicians to do at sites are getting rapidly, I won't say exponentially, but rapidly more expensive. That is to say, less efficient. The pass-through issue, you're right, it does wax and wane. If you think about pre-COVID, peak COVID, post-COVID, and now, the percentage that is pass-throughs has waxed and waned, albeit the data would suggest it's starting to moderate. Nigel, you might want to expand.

Nigel Clerkin
CFO, ICON Public Company

Well, Dave, yeah, I mean, certainly pass-throughs have been increasing. We've talked about that. Like, pass-throughs as a percentage of revenue have gone from 25% of revenue, roughly in 2024 to year- to- date about 32%. So they certainly have increased and actually, are still continuing to increase to some degree in backlog as well. When you look at our trailing 12-month book-to-bill, it's 1.3x on a direct fee basis and 1.46x on a ASC 606 basis. That said, to Barry's point, when you look at our overall backlog, and you normalize for the fact that how we treat FSP awards, we only ever take 12 months into backlog. So when you adjust for that, the proportion within our total backlog, it's a bit higher than the current proportion of revenue. It's probably around 37%, 38%, somewhere around there.

Will you still expect to see some increase in the level of pass-throughs in proportion of overall revenue modestly over time? But I don't expect it to be at the same sort of ramp as we've seen in the last couple of years. It should start to stabilize a bit more from here. We would expect based on what we can see today.

Barry Balfe
CEO, ICON Public Company

Notwithstanding the pass-through effect, we've seen quarter-over-quarter earnings progression, which we predicted and committed. We'll see year-over-year earnings progression. The margin piece will have some noise attached to it. If you look at the margin profile over the last number of years, we're probably 400 basis points down on where we were in 2024. Roughly 200 basis points of that 400 basis points is just pass-through noise.

So the ballgame for us is about taking these exceptional industry-leading commercials, taking these capabilities that are resonating disproportionately with customers, and driving conversion in such a fashion that we create value for patients, there's societal value, for customers, there's commercial value, but return some value to our shareholders and candidly, our teams, to make sure that at the same time that we're building these capabilities, there is incremental margin gain. There will be operating leverage as direct fees return to growth.

Last quarter was the first quarter in some time where direct fee volumes increased sequentially. This quarter will be the first quarter in some time where we expect them to increase on a year-over-year basis, and we should see that accelerate as the impact of the trailing 12-month book-to-bill on direct fees of 1.3x begins to become more relevant than the preceding 12 months of 1.0x that preceded it.

Dave Windley
Healthcare Equity Research, Jefferies

Got it. So, Nigel, did I hear you say adjusting for the FSP inclusion, 37%-38% would be the intensity? So the difference would still be something like 32 year- to- date versus 37.8 ?

Nigel Clerkin
CFO, ICON Public Company

Yeah. So exactly, Dave. So, like, might it increase a little bit more from where it is as a proportion of revenue, maybe to some degree, but probably not at the same pace that it has done in the last two years, obviously, in particular.

Barry Balfe
CEO, ICON Public Company

Yeah. Okay. There's another factor there, which is you don't burn all of the backlog on pass-throughs traditionally. So you would expect to see a higher proportion of pass-throughs in backlog than in revenue because backlog usually has some contingency in there.

Dave Windley
Healthcare Equity Research, Jefferies

Okay. Okay. There are some strategies that would, as you think about selling more services, that actually make some of these things that are pass-through internal marginable revenue.

Barry Balfe
CEO, ICON Public Company

Absolutely.

Dave Windley
Healthcare Equity Research, Jefferies

Like your site network, like technology. How do you think about adding some of those capabilities?

Barry Balfe
CEO, ICON Public Company

I think very carefully about what we need to be expert at. We're experts in delivering laboratory services who used to outsource a lot of our laboratory kit preparation. Now we do most of that in-house. We've opened new labs. We've opened new lab kitting services. We'll open more labs. South America is a very interesting example. Labs and kitting could be very interesting. It's faster. You avoid an awful lot of regulatory hurdles. You can service your customers better and you make a margin on work you used to outsource. You look in areas like medical imaging or cardiac safety, where traditionally the company would have outsourced a proportion of its central reader work. We've now got critical mass on these functions where that makes less and less economic sense.

Site networks, honestly, I think less about it as a margin opportunity in the sense of your question, but it's true. I think more about where is there economic value that's twofold, in the business in its own right and insofar as it augments the company's capacity to have superior site performance, which we believe we do, and it's a competitive advantage we'd like to defend. With that said, in technology, we are extraordinarily selective. I think not just this industry. We are going to see a democratization of coding to a degree that will be a good thing, but those who are less than specific in the bets they make may find that to be counterproductive. We find that our partnerships with people like Microsoft give us a great basis, a great foundation for some of the agentic capabilities we're building.

Our partnerships with Anthropic and others like them enable us to build more of these tools ourselves, to build them on the basis of subject matter expertise that third parties don't have, and thereby not just to eliminate the margin on creating these things, but to eliminate a tremendous amount of time. The ability to stand up agentic capability and workflows much, much more rapidly has the potential to accelerate trials, which has an obvious knock-on for earnings and due course.

Dave Windley
Healthcare Equity Research, Jefferies

Sure. In the last minute that we have here, I want to ask a margin question. The transition from, you know, if we look at 2024 to 2026 or the first half of 2025 to 2026, you had this resetting. There was the accounting investigation, and in the interim, you came out of that, and the guidance for the early part of 2026 started at an EBITDA level that, you know, you would be unaccustomed to, quite a bit lower. How much of that gap do you think you can make up over time?

Barry Balfe
CEO, ICON Public Company

Well, if we take the 400 basis point degradation starting point and say 200 basis point of it is irrelevant pass-through noise, the question is over what period of time. Let's start with the basics. Is it viable that you recoup some, most, or all of the 200 points in time? Why not? Sure. It's not going to be overnight. I think that's going to be a multi-year process of margin expansion, and we also focus on incremental earnings expansion in the first instance. But what I would say to you is that when you think about margins in this business, when this tech disruption settles down in the next two to three years, in addition to having expanded margins over that period, it will be those who are incumbent across the largest proportion of these relationships that are the long-term winners.

As this industry consolidates increasingly down to two or three very large-scale providers, incumbency across biotech, across midsize, across large pharma, as we emerge from 2027, 2028 levels of tech adjustment, I think is going to be the ballgame. We balance, we've talked about this in the context before of capital expenditure. It's no different. We balance our investments in internal capabilities, internal teams. This business only works if we can attract and retain the best and the brightest, and selective M&A activities where there's not just bottom-line accretion, but there's also top-line revenue synergy. If it's reasonably high growth, reasonably high margin, and extremely high right to win for ICON, that's an area where we'll tap into because we think driving in parallel margin expansion and market share gains in this critical period will be the key to unlocking the value over time.

Dave Windley
Healthcare Equity Research, Jefferies

Excellent. I think we landed the plane almost on time.

Barry Balfe
CEO, ICON Public Company

I bet so.

Dave Windley
Healthcare Equity Research, Jefferies

Thank you very much.

Barry Balfe
CEO, ICON Public Company

Thanks, Dave.

Dave Windley
Healthcare Equity Research, Jefferies

Good to have you both.